Evotec (EVT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting of Shareholders scheduled for August 7, 2024, at the principal office in Boston, MA, for five Eaton Vance funds.
Main agenda is the election of Class III Trustees for each fund, with specific nominees listed for each.
Record date for voting eligibility is May 28, 2024; proxy materials are available online.
Shareholders are encouraged to vote by proxy even if not attending in person; proxies are revocable.
Voting matters and shareholder proposals
Election of Trustees is the sole proposal; each fund votes separately, and votes are not aggregated.
Nominees for each fund are current Trustees, and the Board recommends voting FOR all nominees.
Shareholder proposals for the 2025 Annual Meeting must be received by February 24, 2025, for inclusion.
Other business may be considered if properly presented at the meeting.
Board of directors and corporate governance
Each Board consists of ten noninterested Trustees, all serving staggered three-year terms.
Trustees are selected based on experience, diversity of skills, and ability to contribute to effective oversight.
The Board has six standing committees: Audit, Contract Review, Governance, Portfolio Management, Compliance Reports and Regulatory Matters, and Ad Hoc for Closed-End Fund Matters.
Trustees are compensated via annual retainers and committee service fees, with the option to defer compensation.
Latest events from Evotec
- Transformation targets €75M savings by 2027 and >€1B revenues with 20%+ EBITDA margin by 2028.EVT
Status update10 Mar 2026 - Strong JEB growth, asset-light pivot, and robust pipeline drive mid-term value creation.EVT
Company presentation10 Mar 2026 - Revenue up 2%, but losses deepen and restructuring accelerates for 2025 recovery.EVT
Q2 20241 Feb 2026 - Biologics growth and cost savings offset R&D softness, supporting 2024 guidance.EVT
Q3 202416 Jan 2026 - Strong Q4, cost savings, and biologics growth set up 5–10% revenue rise in 2025.EVT
Q4 20242 Dec 2025 - Annual meeting to elect Trustees, highlight board diversity, and reinforce audit oversight.EVT
Proxy Filing2 Dec 2025 - JEB grew 16% as group revenues fell 5%, with a strategic reset and €300m asset sale planned.EVT
Q2 202523 Nov 2025 - Q1 revenue fell 4% but Biologics grew 10–11%; guidance and cost savings remain on track.EVT
Q1 202519 Nov 2025 - JEB growth and a major Sandoz deal offset D&PD softness, supporting 2025 guidance.EVT
Q3 202513 Nov 2025